Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8056184rdf:typepubmed:Citationlld:pubmed
pubmed-article:8056184lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:8056184lifeskim:mentionsumls-concept:C1704689lld:lifeskim
pubmed-article:8056184lifeskim:mentionsumls-concept:C0019764lld:lifeskim
pubmed-article:8056184lifeskim:mentionsumls-concept:C0023175lld:lifeskim
pubmed-article:8056184lifeskim:mentionsumls-concept:C0004368lld:lifeskim
pubmed-article:8056184lifeskim:mentionsumls-concept:C0333348lld:lifeskim
pubmed-article:8056184lifeskim:mentionsumls-concept:C0018591lld:lifeskim
pubmed-article:8056184lifeskim:mentionsumls-concept:C1883709lld:lifeskim
pubmed-article:8056184pubmed:issue5lld:pubmed
pubmed-article:8056184pubmed:dateCreated1994-9-12lld:pubmed
pubmed-article:8056184pubmed:abstractTextThe hypothesis was tested that islet autoimmunity is induced by ongoing islet cell destruction in subjects with susceptibility genes HLA-DR 3 and/or DR 4. Sixty-one patients with confirmed chronic pancreatitis were analysed, 30 of whom expressed HLA-DR 3 and/or DR 4. Electron microscopy studies in 10 patients showed that the inflammatory process also affected islets, as recognisable from islet cell lysis, intrainsular fibrosis and immune cell infiltrates. None of the sera tested contained any of three markers of islet autoimmunity, ICA, IAA or GAD antibodies. A correlation was seen between the loss of exocrine function, as determined by the ALTAB-test, and of beta-cell function, as determined by the C-peptide response to i.v. glucagon. However, there was no preferential loss of beta-cell function in patients with HLA-DR 3 and/or DR 4. We conclude that islet cell destruction occurs during chronic pancreatitis, but does not trigger islet autoimmunity, even in the presence of HLA-DR 3 and/or DR 4.lld:pubmed
pubmed-article:8056184pubmed:languageenglld:pubmed
pubmed-article:8056184pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8056184pubmed:citationSubsetIMlld:pubmed
pubmed-article:8056184pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8056184pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8056184pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8056184pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8056184pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8056184pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8056184pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8056184pubmed:statusMEDLINElld:pubmed
pubmed-article:8056184pubmed:monthMaylld:pubmed
pubmed-article:8056184pubmed:issn0012-186Xlld:pubmed
pubmed-article:8056184pubmed:authorpubmed-author:KolbHHlld:pubmed
pubmed-article:8056184pubmed:authorpubmed-author:ChristieM RMRlld:pubmed
pubmed-article:8056184pubmed:authorpubmed-author:BertramsJJlld:pubmed
pubmed-article:8056184pubmed:authorpubmed-author:LohmannDDlld:pubmed
pubmed-article:8056184pubmed:authorpubmed-author:Kolb-Bachofen...lld:pubmed
pubmed-article:8056184pubmed:authorpubmed-author:LampeterE FEFlld:pubmed
pubmed-article:8056184pubmed:authorpubmed-author:HeiseJ WJWlld:pubmed
pubmed-article:8056184pubmed:authorpubmed-author:SeifertIIlld:pubmed
pubmed-article:8056184pubmed:issnTypePrintlld:pubmed
pubmed-article:8056184pubmed:volume37lld:pubmed
pubmed-article:8056184pubmed:ownerNLMlld:pubmed
pubmed-article:8056184pubmed:authorsCompleteYlld:pubmed
pubmed-article:8056184pubmed:pagination471-5lld:pubmed
pubmed-article:8056184pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:8056184pubmed:meshHeadingpubmed-meshheading:8056184-...lld:pubmed
pubmed-article:8056184pubmed:meshHeadingpubmed-meshheading:8056184-...lld:pubmed
pubmed-article:8056184pubmed:meshHeadingpubmed-meshheading:8056184-...lld:pubmed
pubmed-article:8056184pubmed:meshHeadingpubmed-meshheading:8056184-...lld:pubmed
pubmed-article:8056184pubmed:meshHeadingpubmed-meshheading:8056184-...lld:pubmed
pubmed-article:8056184pubmed:meshHeadingpubmed-meshheading:8056184-...lld:pubmed
pubmed-article:8056184pubmed:meshHeadingpubmed-meshheading:8056184-...lld:pubmed
pubmed-article:8056184pubmed:meshHeadingpubmed-meshheading:8056184-...lld:pubmed
pubmed-article:8056184pubmed:meshHeadingpubmed-meshheading:8056184-...lld:pubmed
pubmed-article:8056184pubmed:meshHeadingpubmed-meshheading:8056184-...lld:pubmed
pubmed-article:8056184pubmed:meshHeadingpubmed-meshheading:8056184-...lld:pubmed
pubmed-article:8056184pubmed:meshHeadingpubmed-meshheading:8056184-...lld:pubmed
pubmed-article:8056184pubmed:meshHeadingpubmed-meshheading:8056184-...lld:pubmed
pubmed-article:8056184pubmed:meshHeadingpubmed-meshheading:8056184-...lld:pubmed
pubmed-article:8056184pubmed:meshHeadingpubmed-meshheading:8056184-...lld:pubmed
pubmed-article:8056184pubmed:meshHeadingpubmed-meshheading:8056184-...lld:pubmed
pubmed-article:8056184pubmed:meshHeadingpubmed-meshheading:8056184-...lld:pubmed
pubmed-article:8056184pubmed:meshHeadingpubmed-meshheading:8056184-...lld:pubmed
pubmed-article:8056184pubmed:year1994lld:pubmed
pubmed-article:8056184pubmed:articleTitleInflammatory islet damage in patients bearing HLA-DR 3 and/or DR 4 haplotypes does not lead to islet autoimmunity.lld:pubmed
pubmed-article:8056184pubmed:affiliationDiabetes Research Institute, Heinrich-Heine-University, Düsseldorf, Germany.lld:pubmed
pubmed-article:8056184pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8056184pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed